List of Fycompa drug patents
Fycompa is owned by Eisai Inc.
Fycompa contains Perampanel.
Fycompa has a total of 2 drug patents out of which 0 drug patents have expired.
Fycompa was authorised for market use on 29 April, 2016.
Fycompa is available in suspension;oral dosage forms.
Fycompa can be used as treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy 12 years of age and older; treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy; treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy; treatment of epilepsy.
The generics of Fycompa are possible to be released after 01 July, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6949571 | EISAI INC | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
Jun, 2023
(4 months from now) | |
| US8772497 | EISAI INC | Method for producing 1, 2-dihydropyridine-2-one compound |
Jul, 2026
(3 years from now) | |
Drugs and Companies using PERAMPANEL ingredient
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy 12 years of age and older; Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy; Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy; Treatment of epilepsy
Dosage: SUSPENSION;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic